Background: The indications for initiating long-term opioid treatment (L-TOT) for chronic non-cancer pain (CNCP) are often unclear and associated with problematic use. This study aimed at evaluating the efficacy of stabilizing opioid therapy followed by a sequential opioid tapering off program in CNCP patients. Methods: A randomized clinical trial with a medications stabilization period (Phase 1) was followed by an opioid tapering off program (Phase 2). In Phase 2, patients were randomized to Control Group (stable treatment) or Taper off Group (sequential opioid dose reduction) and assessed at baseline, after stabilization and up to 6 months. Primary outcomes: measures of cognitive function; secondary outcomes: pain, sleep, rest, quality of life, depression, anxiety, opioid misuse and opioid withdrawal symptoms. Results: In all, 274 patients were screened; 75 were included, out of which 40 dropped out before Phase 2. Those who succeeded Phase 1 (n = 35) had weak/moderate improvements of psychomotor function (p = 0.020), sleeping hours (p = 0.031), opioid withdrawal symptoms (p = 0.019), measures of quality of life (p ≤ 0.043) and opioid misuse scores (p = 0.003). In Phase 2, patients in Taper off Group (n = 15) experienced stable pain intensity and felt significantly more rested at third assessment than the Control Group (n = 20). Conclusions: The opioid tapering off program was not successful due to the vast number of dropouts. Phase 1 was associated with weak to moderate improvements on psychomotor function, sleeping, opioid withdrawal symptoms, quality of life and reduced risk of opioid misuse. In the intervention group of Phase 2, pain intensity was stable and patients felt more rested. Significance: This trial showed that sequential tapering off L-TOT in CNCP patients may be an unfeasible approach. However, improvements after opioid treatment stabilization were achieved and stable pain intensity in those tapered off may encourage the development of more refined programs.
Background
Long-term opioid treatment (L-TOT) of chronic noncancer pain (CNCP) has become a common medical practice in Denmark and other western countries (Toblin et al., 2011; Kurita et al., 2012; Birke et al., 2017) . However, there is still a lack of information regarding efficacy on L-TOT (Dowell et al., 2016) . Epidemiological studies of the Danish population have demonstrated that L-TOT for CNCP did not provide advantages regarding pain control, quality of life and functional capacity Birke et al., 2017) . Moreover, relationships between duration of opioid treatment and the risk of deleterious effects on work and other activities (Birke et al., 2017) , as well numerous adverse effects of L-TOT, have been discussed . Unfortunately, the low capacity of multidisciplinary pain centres and the high prevalence of CNCP in Denmark (Kurita et al., 2012) preclude most patients with CNCP from being referred and typically only patients with complex pain conditions and/or patients with problematic opioid use are admitted to specialized treatment.
Opioid guidelines have consistently been published in an attempt to give directions for responsible prescribing apparently with modest influence on practice (Manchikanti et al., 2017) . In 2016, the United States' Centers for Disease Control and Prevention published 'Guideline for Prescribing Opioids for Chronic Pain', in which the main messages were that non-opioid therapy should be preferred for treatment of CNCP and that opioids should be used only when benefits for pain and function are expected to outweigh risks associated with long-term opioid therapy as side effects, problematic opioid use, overdose and death (Dowell et al., 2016) . Furthermore, recommendations include assessing suitability of the treatment for the patient, initiating a trial of the therapy, monitoring and assessing effectiveness, adherence and side effects (Chou et al., 2009; Manchikanti et al., 2017) . Among the Nordic countries, only Norway has an official guideline for L-TOT of CNCP (The Norwegian Directorate of Health, 2016) . In Denmark, there are no formal guidelines regarding opioid prescribing in CNCP and the annual prescription of opioids has over the last two decades increased to 5.7% among CNCP patients (Birke et al., 2016) . The more cautious prescription of opioids and the lower consumption may be associated with more responsible prescription behaviour due to a strict guideline.
We conducted the present study based on the assumption that L-TOT for CNCP in Denmark is prescribed for CNCP of moderate to severe intensity and that the main recommendations of international guidelines for prescribing opioids are not followed and/or not known. We hypothesized that stabilization and subsequent discontinuation of L-TOT could improve several outcomes in patients with CNCP, including cognitive function, which may be directly affected by opioids (Kurita et al., 2015) . The aims were therefore to develop and evaluate a tapering off program for CNCP in L-TOT and to investigate its influence on cognitive function, pain, sleep, rest, anxiety, depression, quality of life, risk of opioid misuse and opioid withdrawal symptoms.
Methods

Study design, setting and ethics
This prospective, single-centre, open-label, parallelgroup randomized controlled trial (1:1) was conducted at the Multidisciplinary Pain Centre of Rigshospitalet, Copenhagen University Hospital, Denmark (February 2009 -December 2014 .
In all, two phases with nine assessments were planned. The Phase 1 was the stabilization phase and consisted of the two assessments: the first assessment (baseline) was done when patients were admitted to the pain centre and the second assessment was done when medical treatment was considered stable for at least 3 weeks (stable dose levels and regular intervals). At the very same day of second assessment, patients were randomized to receive the intervention (Taper off Group) or continue the same stable treatment (Control Group). The Phase 2 was the opioid tapering off phase, in which patients were randomized to either Control Group or Taper off Group, following seven assessments: third and fourth assessments were done in intervals of 2-3 weeks and the following assessments (fifth to ninth) with intervals of 1 month in between (Fig. 1) .
The study was approved by the Regional Ethics Committee of Copenhagen in Denmark (H-B-2008-061) and by the Danish Data Protection Agency for Health Science Research (jnr. 2014-41-3549) . The study was conducted according to the principles of the Declaration of Helsinki.
Patients and sample size
Eligible participants were consecutive outpatients from a waiting list to the pain centre aged 18 years or more, at least 7 years of schooling, pain duration of at least 6 months, treatment with oral opioids for more than 3 months and daily opioid dose ≥60 mg of oral morphine equivalent. The exclusion criteria were individuals not fluent in Danish language, cancer disease, poor general health condition (incapacity to maintain a conversation or physically debilitated to come to the assessments), enrolled in other studies, pregnancy, dementia, encephalopathy, brain damage, cranial base trauma, renal or hepatic failure 1 Eligible n = 141 Dropout (n = 33) Declined to continue in the study (n = 8) Health condition/hospitalization/surgery (n = 9) Discharged from the center (n = 6) Changes on the treatment (n = 6) Lost contact (n = 4) 5th assessment (n = 16) (Discontinued: change on treatment n = 1, skipped assessment n = 1) 6th assessment (n = 15) (Discontinued: change on medication n = 2, memory problems n = 1) 7th assessment (n = 14) (Discontinued: change on treatment n = 1) 8th assessment (n = 12) (Discontinued: change on treatment n = 1, arms/hands problem n = 1) 9th assessment (n = 12) 3rd assessment (n = 20)
Allocated to control group (n = 20)
3rd assessment (n = 15) Allocated to taper off group (n = 15) 5th assessment (n = 6) (Discontinued: change on treatment n = 2, pain/could not reduce opioid n = 3, declined to continue in the study n = 1) 6th assessment (n = 4) (Discontinued: pain n = 1, change on treatment n = 1) 7th assessment (n = 3) (Discontinued: could not reduce the dose n = 1) 8th assessment (n = 2) (Discontinued: change on treatment n = 1) 9th assessment (n = 1) (Total wean offat 8th assessment n = 1) 
Allocation
Follow
Randomized (n = 35)
Lost to follow-up (n = 7) Did not want to reduce opioid (n = 2) Health condition/pain (n = 2) Declined to continue in the study (n = 1) Discontinued medication by him/herself (n = 1) Lost contact (n = 1) Phase 1 Treatment stabilization 4th assessment (n = 18) Discontinued participation (change on medication/overdose n = 1, hospital too far from home n = 1) 4th assessment (n = 12) Discontinued participation (change on medication n = 1, pain n = 2) Analysis until 4th assessment 1st assessment (n = 72) 3 patients already in stable treatment started at the second assessment Screened n = 274
Not meeting inclusion criteria (n = 96) Absent (n = 25) Refused to be treated at the center (n = 7) Discharged from the clinic (n = 5) Excluded (n = 199) and other metabolic disturbances (medical diagnose) given in the patients' records.
Phase 2 Opioid tapering off
The original sample size of 65 patients per group was determined based on a detectable statistical difference of 3.5 ms on the Continuous Reaction Test 10th percentile (SD 7 ms), with a two-sided 5% significance level and a power of 80%. The selection of this variable to calculate the sample size was based on a previous study with similar patients, in which the test continuous reaction time (CRT) demonstrated capability in discriminating between groups with/without opioid treatment (Sjøgren et al., 2005) . It was anticipated that a 24-month inclusion period would be necessary to recruit 130 patients; however, exclusion and dropout rates were much higher than expected and the authors decided that the study should be time-limited and the last patient was enrolled in January 2014 (duration of 5 years).
Procedure
Eligible patients were informed and invited by letter or telephone contact to participate in the study. At the day of the first medical appointment, the research nurses gave further study information to the patients after which they accepted or declined to participate in the study. Those who accepted gave written informed consent. Assessments and random assignment were executed by the research nurses, who collected data from the patients and their medical charts. The research nurses also explained how the patients should fill in questionnaires and perform each test, and oriented about the opioid dose reduction in the intervention group at each assessment. The duration of each assessment session was between 60 and 90 min.
Randomization and intervention
All patients included in the study went through Phase 1 according to the clinical routine of the service, in which the multidisciplinary pain team aimed at stable opioid dose level and regular and clockwise use of sustained released opioids (fentanyl, hydromorphone, morphine, oxycodone, tramadol) or methadone (Thomsen et al., 1999; Højsted et al., 2006) . Therefore, patients treated with immediate release opioids on demand had their medication changed to a sustained released opioid and their doses were adjusted to optimal pain relief without side effects as nausea, vomiting or sedation. Those already on sustained released opioids had their doses adjusted or the medication substituted by another sustained released opioid, if judged necessary. Other non-pharmacological treatment modalities to manage pain and other symptoms could be discontinued or supplemented during Phase 1. Randomization (1:1) was done by the research nurses using a sealed envelope system to Phase 2: Control Group (no changes of medical treatment -opioids and adjuvant medication -for the next 6 months) or Taper off Group (scheduled opioid dose decrease to opioid discontinuation in 6 months).
The taper off intervention consisted of a reduction of 10% of the daily opioid dose every week until discontinuation of opioid treatment for up to 6 months. Patients, who had difficulties in dose reductions every week, were switched to dose reductions every 2 weeks. When a 10% reduction was not possible due to the limited available dosage in the market, it was approximated to the next available smaller dose and the daily distribution of the doses was adjusted as close as possible of the planned reduction. Clonidine use (25-150 lg/day) was allowed in cases of opioid withdrawal symptoms, according to medical prescription (adapted from Washington State Agency Medical Directors ' Group, 2007) . Encouragement to continue opioid dose reductions was delivered at each assessment by the research nurses and it was based on simple reminders of when to start the next dose reduction. The multidisciplinary team was informed at several meetings about the study protocol and practical procedures were outlined. Thus, the team explained to the patients the possible advantages of opioid discontinuation (e.g. less cognitive dysfunction, better general well-being and even in some patients less pain intensity) and further they informed details about the potential disadvantages of the opioid tapering off program (e.g. withdrawal symptoms including general discomfort, increasing pain intensity, sweating, abdominal cramp, etc.).
The patients in the Control Group were maintained on the same treatment for the next 6 months without changes of medications. They were also informed that after the 6 months they could choose to discontinue the opioid treatment according to the schedule and support given in the intervention group. Alterations on patient's health status that implicated in treatment changes during the study period were reasons for dropouts.
Treatment was provided by the multidisciplinary team of the pain centre, which was primarily composed of three pain specialist physicians certified by the Nordic Course in Advanced Pain Medicine (http://www.ssai.info/education/pain-education/) and four experienced clinical nurses. In addition, a psychologist, social worker and physiotherapist were also a part of the team and could be included if needed. Appointments and clinical decisions were exclusively handled by the pain team. The nurses at the Multidisciplinary Pain Centre who were involved in the treatment reinforced the procedures of each treatment arm and followed-up patients in both groups by telephone appointments according to the clinical routine.
Measures and instruments
Assessments followed the same procedure for both groups (Fig. 1) . Data collected in each assessment are described below.
(1) At baseline (1st assessment): socio-demographics (sex, age, co-habitation, schooling, work and income), pain characteristics (type, number of localizations and duration in years) and opioid treatment duration in years. (2) At baseline, second and last (9th) assessments: quality of life, risk for opioid medication misuse and symptoms of opioid withdrawal. (3) At all assessments: pain intensity, equivalent daily oral morphine dose in mg (adapted from Handberg, 2017) , other medications, hours of sleep in the previous night before assessment, sensation of rest, anxiety and depression, and measures of cognitive function.
Primary outcomes
Cognitive assessment was done using five validated neuropsychological tests, which were selected based on our research group's previous scientific work in patients with chronic pain (Sjøgren and Banning, 1989; Banning and Sjøgren, 1990; Banning et al., 1992; Sjøgren et al., 1994 Sjøgren et al., , 2000 Sjøgren, 1997 Sjøgren, , 2006 Kurita and Pimenta, 2008; Kurita et al., 2011) . They were:
(1) Continuous reaction time (CRT) measures sustained attention. It is a computer test (EKHO version 1.3.2410.42508; Bitmatic Odder, Denmark.) that registers the reaction time to respond to the emission of a sound signal. Scores were summarized in milliseconds using 10th (fastest values), 50th and 90th (slowest values) percentiles (Elsass, 1986) . More prolonged times meant worse performance. (2) Finger Tapping Test (FTT) measures psychomotor speed. A mechanical device with a key attached was used to record the number of taps (Peters, 1976) . Score was calculated by the numbers of taps. Higher scores meant better performance. (3) Digit Span Test (DST) assesses attention, concentration and working memory (Wechsler, 1981) .
Subjects should repeat orally series of numbers of increasing lengths, in forward and backward orders. Scores range from 0 to 14; higher scores meant better performance. (4) Trail Making Test B (TMTB) assesses visual scanning speed, motor function, attention and mental flexibility. The test consists of two parts (A and B), but in this study only part B was applied. In this test, numbers and letters written on a paper should be connected in alternated sequence and increasing order. Score was calculated by the time spent to correctly conclude the test (seconds). Shorter time meant better performance (Reitan, 1958) . (5) Mini-mental State Examination (MMSE) measures orientation to time and place, registration of words, attention, calculation, and word recall, as well as language and visual construction (Folstein et al., 1975) . Scores range from 0 to 30; scores below 27 are considered indicative of cognitive impairment.
Secondary outcomes
Pain intensities at the moment of the assessment (pain right now) and in average (average pain) were assessed through verbal numerical scale from 0 to 10. Sleep was measured in hours of sleep in the previous night before assessment and rest sensation was answered by the patients as feeling rested or not rested. In addition, depression and anxiety were evaluated by the hospital anxiety and depression scale (Zigmond and Snaith, 1983) . In this study, we also analysed the physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain and general health using the RAND 36-Item Short Form Health Survey version 1.0 (SF-36) (Ware and Sherbourne, 1992) .
The risk for opioid medication misuse in patients with chronic pain was assessed by the Pain Medication Questionnaire (PMQ) (Adams et al., 2004) , which has been validated in opioid-treated chronic pain patients in the Danish language (Højsted et al., 2011) . Higher score means higher risk of opioid misuse. Scores equal or above 22 were considered indicative of opioid addiction risk (Højsted et al., 2011) .
The Subjective Opiate Withdrawal Scale (SOWS) and Objective Opiate Withdrawal Scale (OOWS) are instruments to assess the presence and intensity of opioid withdrawal symptoms. They are based on a self-reported scale and on an observer-based scale, respectively (Handelsman et al., 1987) .
Statistical analyses
Patients baseline characteristics were compared between those included and those who refused to participate in the study, those randomized and dropouts, and control and intervention groups applying Chi-square and Wilcoxon two-sample test. Patients, who remained in the study, and patients, who dropped out during the course to the third assessment, were also compared using Wilcoxon test. In addition, to analyse the effect of treatment stabilization over time, mean changes on the outcome variables from first to second assessment were examined in those who participated in both assessments using Wilcoxon Signed Rank Test. Outcomes variables were also compared between the control and intervention groups at each assessment applying Chisquare test and Stratified Wilcoxon test adjusted for sex differences.
During Phase 1, the number of patients using adjuvant medications was compared between the first and second assessments. Very few patients used other medications than opioids in Phase 2. Consequently, analysis of differences between groups regarding medication use was considered irrelevant.
Effect sizes were not calculated due to the reduced sample size and intention-to-treat analysis was not applicable. However, the significance level was classified in intervals: 0.01 < p < 0.05 indicated that there may be a weak effect of the intervention on the outcome, 0.001 < p < 0.01 indicated that there may be a moderate effect of the intervention on the outcome and p < 0.001 strongly indicated that there may be an effect of the intervention on the outcome (Johnsen et al., 2014) .
All analyses were performed in SAS version 9.1 (SAS Institute, Cary, NC, USA).
Results
Number of CNCP patients assessed
During the study period, 274 patients were screened from a waiting list to the multidisciplinary pain centre, out of which 75 (27.4%) were included in Phase 1 of the study. In all, 35 (46.7%) were randomized to Phase 2, but only 13 remained in the study and completed the final assessment. Therefore, the statistical analyses covered the first four assessments, in which at least 30 patients were assessed. Some patients dropped out immediately after disclosure of the group they were randomized to and, therefore, the number of patients in the groups ended up imbalanced. Numbers and reasons for exclusion and dropout are shown in Fig. 1 .
Characteristics of patients and dropouts
Included patients (n = 75) were 56% female, mean age 50.9 year (SD = 11.4), 82.6% had nociceptive somatic pain alone or mixed with neuropathic pain, and 52% had one or two pain localizations. Participants and non-participants (patients that refused to participate in the study) did not differ regarding sex, age, pain type and number of pain locations (Table 1 ). In the Phase 2, randomized patients and those who dropped out were similar regarding most characteristics, but randomized patients had significantly higher income (p = 0.048) and longer pain duration (p = 0.042) ( Table 1) .
3.3 Baseline clinical comparison of randomized patients who remained in the study and those who dropped out during the course to the third assessment Pain intensity, cognitive function variables and almost all scales of SF-36 did not differ between the patients, who completed the four assessments (n = 32) and those who did not (n = 40). Patients who dropped out presented worse scores of anxiety (p = 0.019), depression (p = 0.106), general health (p = 0.047) assessed by SF-36 and higher risk for opioid misuse assessed by PMQ (p = 0.015) ( Table 2) .
Baseline comparison of intervention and control groups
Intervention and control groups were similar regarding socio-demographic variables, pain characteristics and opioid dose at baseline. However, they differed regarding sex distribution (p = 0.037) as there were more women in the control group (75%) and more men in the intervention group (60%) ( Table 3) .
Phase 1: outcomes
Effects of stable treatment were analysed by comparison of clinical data from patients, who participated in the first and second assessments. In all, 42 (58.3%) out of 72 patients achieved stable treatment (Fig. 1) . The mean time of the Phase 1 (from first to second assessment) was 242.1 days (SD = 237.8) and there was an increase in the daily morphine equivalent mean dose of 29.5 mg (SD = 277.9) ( Table 4 ). In addition, more patients were treated with adjuvant medications at the second assessment (1st/2nd assessments: n = 39/n = 42, antidepressants 33.3%/47.6%, anticonvulsants 30.8%/35.7%, benzodiazepine 12.8%/16.7%, muscle relaxant 7.7%/11.9% (baclofen, chlorzoxazone and dantrolene), antipsychotic 0%/4.8%, antiarrhythmic 0%/2.4%, psychostimulant 2.6%/2.4% and other 20.5%/19.5%).
Primary outcomes: a weak positive effect (improvement) was observed in the cognitive test FTT in the non-dominant hand (p = 0.018).
Secondary outcomes: weak positive effects were also observed regarding duration of sleeping (longer duration, p = 0.031), SOWS (lower scores, p = 0.019) and physical functioning (higher scores, p = 0.043) and emotional well-being (higher scores, p = 0.040) according to SF-36. Moderate positive effects were detected for other two scales of SF-36, energy fatigue (higher, scores, p = 0.001) and social functioning (higher scores, p = 0.003) and a strong positive effect on the pain scale of SF-36 (lower ratings, p < 0.001) was observed (Table 4) . A moderate positive effect was also noted on PMQ (lower scores, p = 0.003) (Table 4) . Moreover, 14 patients had PMQ score ≥22 at the first assessment and score below 22 on the second assessment (lower risk for opioid misuse), whereas only three patients with score below 22 at the first assessment had a score increase to ≥22 at the second assessment (higher risk for opioid misuse). No significant deterioration of the stable treatment was noted on any other measures.
Phase 2: outcomes
In the comparison between intervention and control group between the first and fourth assessments, patients in the Control Group had on average 1.5 (SD = 2.6) contacts/appointments with the pain team, while the Taper off Group had 4.3 (SD = 2.1) contacts/appointments. In addition, pain average (p = 0.032) and pain right now (p = 0.031) differed between groups at the second assessment, but the taper off process had not started at that point. Primary outcomes: no significant differences on the measures of cognitive function were noted (Table 5) .
Secondary outcomes: patients in the intervention group felt significantly more rested at the third assessment (35% control vs. 80% intervention, p = 0.0082, strong effect).
Discussion
This randomized clinical trial launched the hypothesis that stabilization followed by tapering off could improve several outcomes in CNCP patients on L-TOT. The stabilization phase of L-TOT was associated with weak to moderate improvements on psychomotor function, sleeping, opioid withdrawal symptoms, quality of life, and risk of opioid misuse and strong effect on pain relief. However, more than half of the patients included were not able to complete Phase 1 of the study. Furthermore, the opioid tapering off program proved to be even more difficult. Nevertheless, the few patients, who were able to reduce opioid dose did not develop severe withdrawal symptoms including increasing pain intensity when compared to the control group. On the contrary, more patients in the intervention group felt rested at the third assessment. However, it should be noted that the number of patients was substantially reduced increasing the risk of type II errors. As described previously, a prerequisite for the present study was based on the assumption that CNCP patients in Denmark are generally started on L-TOT without clear indications and certainly not in accordance with existing guidelines (Manchikanti et al., 2017) . Moreover, it must be taken into account that the most burdened and complex patients are referred to multidisciplinary pain management units and therefore they are not representatives for the general pain population although they may represent the tip of an iceberg . Studies have reported that an increasing number of patients are already treated with opioids at referral to specialized pain management (70-80%) (Becker et al., 1997; Kouyanou et al., 1997; Nissen et al., 2001) and they often present problematic opioid use (Højsted et al., 2010 (Højsted et al., , 2011 . These findings are in line with population-based studies from Denmark, which repeatedly have demonstrated that L-TOT in the majority of CNCP patients was associated with poor quality of life, high pain intensity and low functional capacity Birke et al., 2017) . Therefore, tapering off L-TOT in CNCP patients seems to be justified.
The patients that remained in the present trial, until it was judged that a stable and regular medication schedule was obtained, were probably those with sufficient motivation and coping skills. It has formerly been demonstrated that multidisciplinary pain management is efficient; however, response rates to treatment of CNCP may be considered modest (Becker et al., 2000) . A long and exhausting trial lasting 5 years has passed by resulting in a failed trial of opioid tapering off due to dropouts. This has resulted in an underpowered study regarding Phase 2. Besides the collected information on reported reasons for dropouts, opioid dependence may be another plausible explanation for dropping out of the study. In Denmark and elsewhere, multidisciplinary pain centres may not be geared for managing addictive behaviours and do not have integrative programs with addiction medicine. Traditionally, their main focus is on holistic pain management approach. On the other hand, addiction medicine programs rarely include CNCP patients with problematic opioid use (Bailey et al., 2010) . Although our study is hampered by a vast dropout rate, we still feel that it is highly justified to point to the fact that the stabilization of opioid treatment is not a simple task and opioid tapering off seems to be extremely difficult in CNCP patients in general -not only in those with problematic opioid use (Blondell et al., 2010) . Therefore, it is also a matter of how ambitious pain centres should be in the event of problematic opioid use. Should stabilization of L-TOT be the goal or should opioid tapering off be initiated? We certainly hope that the present article can contribute to this debate and further development. Expert guidelines have recommended sequential dose reduction and use of adjuvant medications to treat withdrawal symptoms (Manchikanti et al., 2012; Berna and Rathmell, 2015; Washington State Agency Medical Directors' Group, 2015; Dowell et al., 2016) . However, the evidence regarding opioid tapering off programs is very limited. A Cochrane review on interventions for reduction of prescribed opioid use found only two studies, which were focused on non-pharmacological strategies to reduce pain and, consequently, opioid use in CNCP (Windmill et al., 2013) .
Another randomized controlled trial recently tested a program to taper off L-TOT in CNCP (Sullivan et al., 2017) . The program consisted of psychiatric consultations, opioid dose tapering off and weekly sessions based on cognitive-behavioural therapy, which was compared with usual care. Similar to our investigation, difficulties in enrolment and dropouts resulted in an underpowered sample. However, the taper off group improved significantly compared to the usual care group regarding self-report of pain interference, pain self-efficacy and prescription-related problems at 22 weeks after randomization. Analyses of opioid misuse and opioid craving did not show differences between groups (Sullivan et al., 2017) . Noteworthy, as demonstrated in our study, the groups did not differ regarding opioid dose and pain intensity, which indicated that L-TOT in some of these patients may be dispensable. In addition, considering the limitations of retrospective designs, there are studies that reviewed patients' charts and reported improvements on pain, mood and function following interdisciplinary rehabilitation programs for CNCP, which included opioid tapering off or cessation (Murphy et al., 2013; Cunningham et al., 2016; Huffman et al., 2017) . *0.01 < p < 0.05; **0.001 < p < 0.01; ***p < 0.001. Another aspect of particular note was the fact that 58.3% of patients included in our study achieved stable treatment, which represents a high level of attainment compared to 34.5% of a previous available retrospective report in a similar sample (Schneider and Kirsh, 2010) . Moreover, opioid dose increased in average of 29.5 mg of oral morphine equivalents, which may be associated with pain relief and improvements on several measures in Phase 1. There is indication that opioid treatment stabilization is beneficial; however, it demands dose increase (Thomsen et al., 1999) . It is possible that some patients were undertreated.
In our study besides unstable health condition, another common reason for dropouts was refusal/ unwillingness to continue in the study. Many patients seemed to fear that their pain condition would deteriorate during opioid tapering off (Berna and Rathmell, 2015; Frank et al., 2016) . However, improvements on function, without worsening pain or even decreasing pain levels have been observed in patients, who discontinue opioid treatment (Berna and Rathmell, 2015; Sullivan et al., 2017) . It is possible that one of the consequences of the exposure to L-TOT is opioid-induced hyperalgesia and that tapering off decreases nociceptive sensitization (Chen et al., 2009; Zhang et al., 2015) . Other perceived barriers for opioid tapering off include pessimism about efficacy of other analgesics and fear of opioid withdrawal symptoms (Frank et al., 2016) . We expected that the multi-professional approach at our pain centre as well as the possibility to manage withdrawal symptoms with clonidine per protocol were ways to overcome the barriers, which could preclude opioid tapering off. However, it was not enough to prevent the dropout rates. The rigorous regime of tapering the dose with 10% every week or every second week may be too tough for the patients. The patients may need much more time for the tapering period and they may even need breaks in the tapering off process depending on the magnitude and nature of abstinences. In addition, pain specialists or even the multidisciplinary team may not be sufficiently educated for this task.
This study has limitations that impede the generalizability of the results and impose caution to draw conclusions. First, the small sample reduced the statistical power to detect differences over the time and between groups. Second, we could not assess the patients that dropped out and perform an intentionto-treat analysis due to ethical reasons (many did not want to participate anymore and several assessment tools were not part of the clinical routine). Third, patients received a multidisciplinary treatment, which was personalized, but we did not collect data to analyse specific factors that may have contributed to improvements in Phase 1 and we recognize the uncontrolled nature of these findings. Last, a carry-over effect from the stabilization period and contact with heath care staff in an open study may be sources of bias. Nevertheless, this study demonstrated the difficulty in stabilizing and tapering off L-TOT in CNCP patients, improvements during stabilization and a promising observation that pain did not increase during tapering off. Observing the sparse literature on this topic, the present data may inspire and encourage the development of new trials involving more efficacious programs of opioid tapering off in CNCP patients. An opioid tapering off program is desirable for to those who experience opioid side effects and/or long-term consequences, which out-weight the benefits, but in particular, it may be suitable for some patients, who develop problematic opioid use. In this case, cognitive-behavioural strategies to increase compliance to the taper off program may be a key component to be investigated in future trials.
Conclusion
Overall, the opioid tapering off program was not successful due to the vast number of dropouts. Phase 1 was associated with some weak to moderate improvements on psychomotor function, sleeping, opioid withdrawal symptoms, quality of life and reduced risk of opioid misuse. In those entering the intervention group of Phase 2, pain intensity did not increase and patients in felt significantly more rested at the third assessment.
